What Is Semaglutide?

Research Overview

Semaglutide is a synthetic glucagon-like peptide-1 (GLP-1) receptor agonist with 94% structural homology to native human GLP-1. It features an aminoisobutyric acid (Aib) substitution at position 8 for DPP-4 resistance and a C18 fatty diacid chain linked via a spacer at Lys26, enabling non-covalent albumin binding that extends its half-life to approximately 7 days.[1][2]

Semaglutide is a GLP-1 receptor agonist that has been the subject of extensive preclinical and clinical research, with large-scale cardiovascular outcomes trials (SUSTAIN, PIONEER, SELECT, STEP, FLOW) enrolling over 40,000 participants collectively. Note: Research-grade semaglutide sold here is not equivalent to any FDA-approved pharmaceutical product.[3][4][5]

Beyond glycemic control and weight loss, research has investigated cardiovascular outcomes (SELECT trial), renal endpoints (FLOW trial), and emerging signals in MASH/NASH, Alzheimer's disease, addiction, and obstructive sleep apnea in research settings.[5][6][7]

The molecule was discovered through a structure-activity relationship optimization program at Novo Nordisk, with the discovery process formally detailed by Lau et al. (2015) in Journal of Medicinal Chemistry. Three structural modifications distinguish semaglutide from native GLP-1: (1) substitution of alanine at position 8 with α-aminoisobutyric acid (Aib) to confer DPP-4 protease resistance; (2) attachment of a C18 fatty diacid via a γ-glutamyl spacer and two AEEAc spacers at lysine-26 to enable reversible albumin binding; and (3) substitution of arginine at position 34 with lysine to direct the acylation site. These changes collectively extend the plasma half-life from approximately 2 minutes (native GLP-1) to approximately 168 hours, enabling once-weekly subcutaneous administration.[1]

Semaglutide is structurally related to the dual GIP/GLP-1 agonist tirzepatide, but acts as a mono-agonist at the GLP-1 receptor only. Comparative research across the incretin agonist class has positioned semaglutide as a benchmark molecule for GLP-1R-selective pharmacology, with extensive published mechanistic, pharmacokinetic, and clinical outcomes data spanning over 60,000 study participants in registrational and outcomes trials.[3][4][9]